Advertisement
Screener

Bluejay Diagnostics, Inc. (BJDX) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

1.4 / 5 stars · 9/32 Roast Me

Bluejay Diagnostics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

Bluejay Diagnostics, Inc. (BJDX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2025-03-31

  • Bluejay Diagnostics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-03-31 was 0.00%.
  • Bluejay Diagnostics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2022-03-31 was 0.00%.
  • Bluejay Diagnostics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
  • Bluejay Diagnostics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
  • Bluejay Diagnostics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2021 was 0.00%.
  • Bluejay Diagnostics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2020 was 0.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month
2024-09-300.00%
10-Q · filed 2024-11-07
2024-06-300.00%
10-Q · filed 2024-08-14
2024-03-310.00%
10-Q · filed 2024-05-15
2023-12-310.00%
10-K · filed 2025-03-31
2023-09-300.00%
10-Q · filed 2023-11-09
2023-06-300.00%
10-Q · filed 2023-08-14
2022-12-310.00%
10-K · filed 2024-03-28
2022-09-300.00%
10-Q · filed 2023-11-09
2022-06-300.00%
10-Q · filed 2023-08-14
2022-03-310.00%
10-Q · filed 2022-05-09
2021-12-310.00%
10-K · filed 2023-03-20
2021-09-300.00%
10-Q · filed 2022-11-09
2021-06-300.00%
10-Q · filed 2022-08-10
2020-12-310.00%
10-K · filed 2022-03-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
OSR Health, Inc. (OSRH)United States$0.004B-0.75
Adagio Medical Holdings, Inc. (ADGM)United States$0.004B
Autonomix Medical, Inc. (AMIX)United States$0.004B
AETHLON MEDICAL INC (AEMD)United States$0.005B
INTELLIGENT BIO SOLUTIONS INC. (INBS)United States$0.005B
Beyond Air, Inc. (XAIR)United States$0.003B-0.01
Vivos Therapeutics, Inc. (VVOS)United States$0.003B-0.26
Sonoma Pharmaceuticals, Inc. (SNOA)United States$0.006B-2.59
NEXGEL, INC. (NXGL)United States$0.002B
INVO Fertility, Inc. (IVF)United States$0.002B-0.71